CLOPIDOGREL (CLOPIDOGREL BISULFATE)
CLOPIDOGREL (CLOPIDOGREL BISULFATE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: CLOPIDOGREL; Generic name: CLOPIDOGREL BISULFATE; Manufacturer: Novadoz Pharmaceuticals LLC.
| Brand name | CLOPIDOGREL |
|---|---|
| Generic name | CLOPIDOGREL BISULFATE |
| Manufacturer | Novadoz Pharmaceuticals LLC |
| Used for | 1 INDICATIONS AND USAGE Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) – For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel tablets are indicate |
| Dosage | 2 DOSAGE AND ADMINISTRATION Acute coronary syndrome ( 2.1 ) – Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. – Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days. Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily orally without a loading dose. ( 2.2 ) 2.1 Acute Coronary Syndrome In patients who need an antiplatelet effect within ho |
| Warnings | WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE The effectiveness of clopidogrel results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [ see Warnings and Precautions (5.1), Clinical Pharmacology (12.3) ]. Clopidogrel at recommended doses forms less of the active metabolite and so has a reduced effect on platelet activity in patients who |
| Active ingredient(s) | CLOPIDOGREL BISULFATE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1447a095-c663-4f05-91d4-f09bfc0c3d42 |